A structurally stable, injectable, & immunocompetent human skin model to assess immunogenicity of therapeutic compounds (White Paper)

Enhance Toxicity Assessments with Human-Relevant Data

Discover how advanced ex vivo human skin models are reshaping toxicity evaluations for therapeutic compounds. This white paper highlights innovative methods to assess immunogenicity, showcasing data presented by Dr. Nicolas Gaudenzio, Genoskin’s Chief Scientific Officer, at the FDA-CRCG Peptide Immunogenicity Workshop in October.

Using Genoskin’s robust platforms, we provide insights to de-risk therapeutic candidates and support non-clinical safety and toxicity assessments, enabling informed decision-making with confidence.

Key highlights include:

• Immunocompetent human skin models: Maintain viability and immune integrity for over 7 days, allowing for the detection of unwanted immune reactions earlier in the drug development process.
• Transcriptomic profiling: Identify changes in gene expression and immune responses critical for understanding compound safety.
• Validated workflows for injectables: From subcutaneous, intradermal and transdermal delivery, ensure reliable and reproducible testing.
• mRNA vaccine administration: Case study illustrates the ability to capture rapid immune responses post-injection.

By leveraging human-relevant models and cutting-edge services, we offer scalable, actionable insights tailored to your development needs, helping you reduce reliance on animal testing while accelerating therapeutic innovation.

Download the white paper now to explore how our services can support your next breakthrough.